- Home
- ERAS vs VGNT Comparison
ERAS vs VGNT Comparison
Compare ERAS & VGNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ERAS | VGNT |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.3B |
| IPO Year | 2021 | 2026 |
Fundamental Metrics
Financial Performance| Metric | ERAS | VGNT |
|---|---|---|
| Price | $17.72 | $43.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $14.25 | N/A |
| AVG Volume (30 Days) | ★ 4.7M | 1.1M |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.23 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $38.44 |
| 52 Week High | $24.28 | $47.19 |
Technical Indicators
Market Signals| Indicator | ERAS | VGNT |
|---|---|---|
| Relative Strength Index (RSI) | 48.36 | 54.13 |
| Support Level | $12.36 | $39.34 |
| Resistance Level | $18.20 | N/A |
| Average True Range (ATR) | 1.24 | 1.81 |
| MACD | -0.36 | 0.54 |
| Stochastic Oscillator | 7.23 | 86.77 |
Price Performance
Historical ComparisonAbout ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.